{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:44:40Z","timestamp":1788277480899,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.nefroe.2026.501576","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:31:57Z","timestamp":1783423917000},"page":"501576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Position statement of the SEN Anemia Working Group: A critical and contextualized adaptation of the KDIGO 2026 anemia guidelines to the Spanish setting"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-1385","authenticated-orcid":false,"given":"Jose","family":"Portol\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jes\u00fas","family":"Puchades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.","family":"Broseta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Auxiliadora","family":"Bajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"de Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2026.501576_bib0005","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2026.501576_bib0010","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.nefro.2022.04.001","article-title":"Epidemiology and treatment of renal anaemia in Spain: RIKAS retrospective study","volume":"43","author":"Cases","year":"2023","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefroe.2026.501576_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s","year":"2021","journal-title":"Front Med."},{"issue":"1S","key":"10.1016\/j.nefroe.2026.501576_bib0020","first-page":"S1","article-title":"KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)","volume":"109","year":"2026","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0025","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.nefroe.2026.501576_bib0030","series-title":"Guideline on haemoglobin cutoffs to define anaemia in individuals and populations [Internet]","year":"2024"},{"key":"10.1016\/j.nefroe.2026.501576_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126493","article-title":"Hepcidin-ferroportin interaction controls systemic iron homeostasis","author":"Nemeth","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.nefroe.2026.501576_bib0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1017\/S0029665107005873","article-title":"Folate and vitamin B12: friendly or enemy nutrients for the elderly","volume":"66","author":"Cuskelly","year":"2007","journal-title":"Proc Nutr Soc."},{"key":"10.1016\/j.nefroe.2026.501576_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28237707","article-title":"New perspectives on circulating ferritin: its role in health and disease","author":"Fonseca","year":"2023","journal-title":"Molecules."},{"key":"10.1016\/j.nefroe.2026.501576_bib0050","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/ndt\/gfaa048","article-title":"The problem with transferrin saturation as an indicator of iron \u201csufficiency\u201d in chronic kidney disease","volume":"36","author":"Besarab","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari","year":"2025","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nefro.2020.11.003","article-title":"Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group","volume":"41","author":"Cases","year":"2021","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefroe.2026.501576_bib0065","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0070","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12078","article-title":"TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients","volume":"18","author":"Gaweda","year":"2014","journal-title":"Hemodial Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0085","article-title":"Effect of maintenance intravenous iron treatment on erythropoietin dose in chronic hemodialysis patients: a multicenter randomized controlled trial","volume":"7","author":"Susantitaphong","year":"2020","journal-title":"Can J kidney Heal Dis."},{"key":"10.1016\/j.nefroe.2026.501576_bib0090","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/ndt\/gfad096","article-title":"Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease","volume":"38","author":"Hasegawa","year":"2023","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0095","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2020101531","article-title":"Serum biomarkers of iron stores are associated with increased risk of all-cause mortality and cardiovascular events in non dialysis CKD patients, with or without anemia","volume":"32","author":"Guedes","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0100","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ajh.23682","article-title":"Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin","volume":"89","author":"Evstatiev","year":"2014","journal-title":"Am J Hematol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0105","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3324\/haematol.2019.245092","article-title":"Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats","volume":"106","author":"Jimenez","year":"2021","journal-title":"Haematologica."},{"key":"10.1016\/j.nefroe.2026.501576_bib0110","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.kint.2021.07.013","article-title":"Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease","volume":"100","author":"Mehta","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0115","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1681\/ASN.2016121350","article-title":"C-terminal fibroblast growth factor 23, iron deficiency, and mortality in renal transplant recipients","volume":"28","author":"Eisenga","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0120","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ekir.2025.01.029","article-title":"Systematic review of the effects of iron on cardiovascular, kidney, and safety outcomes in patients with CKD","volume":"10","author":"Chan","year":"2025","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.nefroe.2026.501576_bib0125","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"Von Haehling","year":"2024","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefroe.2026.501576_bib0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2026.501576_bib0135","first-page":"65","article-title":"Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation","volume":"75","author":"Sari","year":"2017","journal-title":"Neth J Med."},{"key":"10.1016\/j.nefroe.2026.501576_bib0140","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.xkme.2020.01.006","article-title":"Iron administration, infection, and anemia management in CKD: untangling the effects of intravenous iron therapy on immunity and infection risk","volume":"2","author":"Ganz","year":"2020","journal-title":"Kidney Med."},{"key":"10.1016\/j.nefroe.2026.501576_bib0150","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/ndt\/gfad250","article-title":"Anaemia in CKD-treatment standard","volume":"39","author":"Macdougall","year":"2024","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0155","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/ckj\/sfad105","article-title":"The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors","volume":"16","author":"Locatelli","year":"2023","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2026.501576_bib0160","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae205","article-title":"Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance","volume":"17","author":"Dasgupta","year":"2024","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2026.501576_bib0165","series-title":"Informe de posicionamiento terap\u00e9utico de roxadustat (Evrenzo\u00ae) en anemia sintom\u00e1tica asociada a enfermedad renal cr\u00f3nica (PT 78\/2022\/V1)","year":"2022"},{"key":"10.1016\/j.nefroe.2026.501576_bib0170","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European renal best practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0175","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/ckj\/sfad152","article-title":"Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice","volume":"16","author":"Portoles","year":"2023","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2026.501576_bib0180","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.02730608","article-title":"Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis","volume":"4","author":"Parfrey","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0185","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.2012.270","article-title":"Summary of the KDIGO guideline on anemia and comment: reading between the (guide) line(s)","volume":"82","author":"Dr\u00fceke","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0190","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae269","article-title":"Post-transplant renal anemia: a call to action from a national study in routine clinical practice","volume":"17","author":"Portoles","year":"2024","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2026.501576_bib0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5301\/ijao.5000107","article-title":"Changes in whole blood viscosity at low shear rates correlate with intravascular volume changes during hemodialysis","volume":"35","author":"Kim","year":"2012","journal-title":"Int J Artif Organs."},{"key":"10.1016\/j.nefroe.2026.501576_bib0200","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000502633","article-title":"Intra-dialytic hemoglobin changes and cardiovascular events: a cohort study on dialysis outcomes and practice patterns in Japan","volume":"50","author":"Hara","year":"2019","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1681\/ASN.2011060546","article-title":"Correction of postkidney transplant anemia reduces progression of allograft nephropathy","volume":"23","author":"Choukroun","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0210","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ndt\/gfy365","article-title":"The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial","volume":"34","author":"Tsujita","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.6002\/ect.2018.0283","article-title":"Treating posttransplant anemia with erythropoietin improves quality of life but does not affect progression of chronic kidney disease","volume":"18","author":"Pile","year":"2020","journal-title":"Exp Clin Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0220","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13643-024-02709-8","article-title":"A systematic review and meta-analysis of factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents","volume":"13","author":"Chienwichai","year":"2024","journal-title":"Syst Rev."},{"key":"10.1016\/j.nefroe.2026.501576_bib0225","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf252","article-title":"Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge","volume":"18","author":"Portoles","year":"2025","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefroe.2026.501576_bib0230","doi-asserted-by":"crossref","first-page":"e1223","DOI":"10.34067\/KID.0000000000000204","article-title":"Anemia treatment, hemoglobin variability, and clinical events in patients with nondialysis-dependent CKD in Japan","volume":"4","author":"Kuragano","year":"2023","journal-title":"Kidney360."},{"key":"10.1016\/j.nefroe.2026.501576_bib0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1440-1797.2005.00386.x","article-title":"Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients","volume":"10","author":"Cervelli","year":"2005","journal-title":"Nephrology (Carlton)."},{"key":"10.1016\/j.nefroe.2026.501576_bib0240","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.ajkd.2019.04.022","article-title":"The use of erythropoiesis-stimulating agents in patients with CKD and cancer: a clinical approach","volume":"74","author":"Thavarajah","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2026.501576_bib0245","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0250","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000516901","article-title":"Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents","volume":"52","author":"Weir","year":"2021","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","article-title":"2015 Japanese Society for dialysis therapy: guidelines for renal anemia in chronic kidney disease","volume":"3","author":"Yamamoto","year":"2017","journal-title":"Ren Replace Ther."},{"issue":"5 Suppl 3","key":"10.1016\/j.nefroe.2026.501576_bib0260","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","year":"2006","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2026.501576_bib0265","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/ndt\/gfm951","article-title":"Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study","volume":"23","author":"Panichi","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0270","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000358215","article-title":"Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients","volume":"37","author":"Okazaki","year":"2014","journal-title":"Blood Purif."},{"key":"10.1016\/j.nefroe.2026.501576_bib0275","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.nefroe.2026.501576_bib0280","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0285","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0290","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0295","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0300","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0305","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.nefroe.2026.501576_bib0310","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv Ther."},{"key":"10.1016\/j.nefroe.2026.501576_bib0315","unstructured":"Ficha t\u00e9cnica Evrenzo [accessed 15 Dec 2025]. Available from: https:\/\/www.ema.europa.eu\/es\/documents\/product-information\/evrenzo-epar-product-information_es.pdf."},{"key":"10.1016\/j.nefroe.2026.501576_bib0320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000542699","article-title":"Effects of roxadustat on thyroid profiles in patients and animals with chronic kidney disease","volume":"56","author":"Li","year":"2025","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0325","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv Ther."},{"key":"10.1016\/j.nefroe.2026.501576_bib0330","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0335","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0340","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-319-75402-4_22","article-title":"The role of hypoxia, hypoxia-inducible factor (HIF), and VEGF in retinal angiomatous proliferation","volume":"1074","author":"Barben","year":"2018","journal-title":"Adv Exp Med Biol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cophys.2018.12.003","article-title":"Revisiting the role of hypoxia-inducible factors in pulmonary hypertension","volume":"7","author":"Shimoda","year":"2019","journal-title":"Curr Opin Physiol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0350","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00467-017-3849-3","article-title":"HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics","volume":"34","author":"Kular","year":"2019","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0355","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00007890-198109000-00002","article-title":"Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients","volume":"32","author":"Opelz","year":"1981","journal-title":"Transplantation."},{"issue":"Suppl 1","key":"10.1016\/j.nefroe.2026.501576_bib0360","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1432-2277.1994.tb01358.x","article-title":"A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. Leuven Collaborative Group for Transplantation","volume":"7","author":"Vanrenterghem","year":"1994","journal-title":"Transpl Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0365","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00007890-198212000-00010","article-title":"Comparative effects of pregnancy, transfusion, and prior graft rejection on sensitization and renal transplant results","volume":"34","author":"Sanfilippo","year":"1982","journal-title":"Transplantation."},{"key":"10.1016\/j.nefroe.2026.501576_bib0370","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1600-6143.2004.00360.x","article-title":"Predicting kidney graft failure by HLA antibodies: a prospective trial","volume":"4","author":"Terasaki","year":"2004","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefroe.2026.501576_bib0375","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.tp.0000437435.19980.8f","article-title":"Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation","volume":"97","author":"Leffell","year":"2014","journal-title":"Transplantation."},{"issue":"1 SUPPL. 1","key":"10.1016\/j.nefroe.2026.501576_bib0380","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2010.10.007","article-title":"US renal data system 2010 annual data report","volume":"57","author":"Collins","year":"2011","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2026.501576_bib0385","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.hoc.2019.05.002","article-title":"Existing and emerging blood-borne pathogens: impact on the safety of blood transfusion for the hematology\/oncology patient","volume":"33","author":"Wagner","year":"2019","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1016\/j.nefroe.2026.501576_bib0390","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/trf.18472","article-title":"Blood donor West Nile virus screening identifies three autochthonous Usutu virus infections in Spain","volume":"66","author":"Jimenez-Marco","year":"2026","journal-title":"Transfusion."},{"key":"10.1016\/j.nefroe.2026.501576_bib0395","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra1612789","article-title":"Indications for and adverse effects of red-cell transfusion","volume":"377","author":"Longo","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2026.501576_bib0400","first-page":"206","article-title":"Challenges in perioperative blood transfusions in kidney transplantation and the need for patient blood management","volume":"22","author":"Rodr\u00edguez-Espinosa","year":"2024","journal-title":"Blood Transfus."},{"key":"10.1016\/j.nefroe.2026.501576_bib0405","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40620-019-00680-5","article-title":"Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents","volume":"33","author":"Brenner","year":"2020","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0410","article-title":"Transfusion thresholds for guiding red blood cell transfusion","volume":"12","author":"Carson","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.nefroe.2026.501576_bib0415","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2026.501576_bib0420","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nefro.2023.11.001","article-title":"Effect of SGLT2 inhibitors on anemia and their possible clinical implications","volume":"44","author":"Cases","year":"2024","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefroe.2026.501576_bib0425","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia","volume":"55","author":"Packer","year":"2024","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0430","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ehf2.14742","article-title":"Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction","volume":"11","author":"Docherty","year":"2024","journal-title":"ESC Hear Fail."},{"key":"10.1016\/j.nefroe.2026.501576_bib0435","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-025-02685-6","article-title":"Erythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors","author":"Marques","year":"2025","journal-title":"Clin Res Cardiol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0440","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0445","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.nefroe.2026.501576_bib0450","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefroe.2026.501576_bib0455","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1182\/bloodadvances.2025016320","article-title":"Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females","volume":"9","author":"Doi","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.nefroe.2026.501576_bib0460","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12933-025-02805-6","article-title":"Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study","volume":"24","author":"Lee","year":"2025","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0465","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.ajkd.2024.02.015","article-title":"Erythrocytosis and CKD: a review","volume":"84","author":"Aoun","year":"2024","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2026.501576_bib0470","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefroe.2026.501576_bib0475","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M19-2945","article-title":"Effects of interleukin-1\u03b2 inhibition on incident anemia: exploratory analyses from a randomized trial","volume":"172","author":"Vallurupalli","year":"2020","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefroe.2026.501576_bib0480","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0485","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1681\/ASN.0000000654","article-title":"Effects of clazakizumab on anemia and iron metabolism in patients with kidney failure","volume":"36","author":"Neuen","year":"2025","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2026.501576_bib0490","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1185\/030079904X2763","article-title":"The prevalence of anemia in patients with chronic kidney disease","volume":"20","author":"McClellan","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.nefroe.2026.501576_bib0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.nefroe.2026.501576_bib0500","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf138","article-title":"Global, regional and national epidemiology of anemia attributable to chronic kidney disease, 1990-2021","volume":"18","author":"Liu","year":"2025","journal-title":"Clin Kidney J."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426001471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426001471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:45:05Z","timestamp":1787139905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251426001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2013251426001471"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501576","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Position statement of the SEN Anemia Working Group: A critical and contextualized adaptation of the KDIGO 2026 anemia guidelines to the Spanish setting","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2026.501576","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501576"}}